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Introduction: Transducer of Cdc42-dependent actin assembly-1 (Toca-1) recruits actin regulatory proteins to
invadopodia, and promotes breast tumor metastasis. Since metastatic breast tumors frequently harbor mutations in
the tumor suppressor p53, we tested whether p53 regulates Toca-1 expression.
Methods: Normal mammary epithelial cells (HBL-100, MCF10A) and breast cancer cell lines expressing wild-type
(WT) p53 (DU4475, MTLn3) were treated with camptothecin or Nutlin-3 to stabilize p53 to test effects on Toca-1
mRNA and protein levels. Chromatin immunoprecipitation (ChIP) assays were performed to identify p53 binding site
in Toca-1 gene. Stable silencing of p53 and Toca-1 were performed in MTLn3 cells to test effects on invadopodia
and cell invasion in vitro, and tumor metastasis in vivo.
Results: We observed that breast cancer cell lines with mutant p53 have high levels of Toca-1 compared to those
with WT p53. Stabilization of WT p53 led to further reduction in Toca-1 mRNA and protein levels in normal breast
epithelial cells and breast cancer cells. ChIP assays revealed p53 binding within intron 2 of toca1, and reduced histone
acetylation within its promoter region upon p53 upregulation or activation. Stable silencing of WT p53 in MTLn3 cells
led to increased extracellular matrix degradation and cell invasion compared to control cells. Interestingly, the combined
silencing of p53 and Toca-1 led to a partial rescue of these effects of p53 silencing in vitro and reduced lung
metastases in mice. In human breast tumors, Toca-1 levels were high in subtypes with frequent p53 mutations, and
high Toca-1 transcript levels correlated with increased risk of relapse.
Conclusions: Based on these findings, we conclude that loss of p53 tumor suppressor function in breast cancers leads
to upregulation of Toca-1, and results in enhanced risk of developing metastatic disease.Introduction
Metastasis is a complex process in which tumor cells ac-
quire the ability to spread to other tissues via lymphatics
or blood vessels. Invading cancer cells form filamentous
actin (F-actin)-based membrane protrusions called inva-
dopodia, whose extracellular matrix (ECM) degrading
activity allows them to invade through basement mem-
branes and migrate toward blood vessels [1]. Silencing of
key components of invadopodia such as N-WASP or
cortactin, leads to impaired tumor vascularization and* Correspondence: harish_chander@cup.ac.in; andrew.craig@queensu.ca
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unless otherwise stated.reduced metastasis in breast cancer models [2,3]. Inva-
dopodia formation is driven by epidermal growth factor
receptor (EGFR) and Src kinase activation that induce
recruitment of actin regulatory proteins (Cdc42/Toca-1/
N-WASP, cortactin) required for F-actin branching
[4,5]. Transducer of Cdc42-dependent actin assembly-1
(Toca-1, also known as FNBP1L) was first identified as an
essential adaptor protein to allow Cdc42 to release N-
WASP from an autoinhibited state and recruit Arp2/3
complex [6]. Toca-1 is a member of the Cdc42-interacting
protein-4 (CIP4) subfamily of Fer/CIP4 homology-Bin/
Amphiphysin/RVS (F-BAR) proteins. The N-terminal
F-BAR domain of Toca-1 forms a crescent-shaped dimer
that targets Toca-1 to areas of membrane curvature [7,8].
The central PKN homology region-1 (HR1) domain
binds Cdc42GTP, and the C-terminal SH3 domain binds
several actin regulatory proteins, including N-WASP [6],l. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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and cortactin [11].
Several recent studies have identified functions of
Toca-1 in regulating filopodia formation and vesicular
trafficking in neuroblastoma cells [12], EGFR trafficking
to lysosomes [13], and EGFR-driven cell motility and in-
vasion [14]. We recently identified Toca-1 as a compo-
nent of invadopodia in breast cancer cells, and that
silencing of Toca-1 led to reduced incidence of metasta-
sis to the lung in mammary orthotopic xenograft models
[11]. In this study, we also reported that Toca-1 expres-
sion levels are high in triple-negative breast cancer
(TNBC) cell lines, which lack expression of estrogen re-
ceptor (ER)/progesterone receptor (PR)/human epider-
mal growth factor receptor 2 (HER2) receptors.
TNBC frequently harbor mutations in the tumor sup-
pressor p53, resulting in both loss-of-function and gain-
of-function effects on p53 pathways [15,16]. In addition
to loss of an appropriate DNA damage response, these
cancers are also more invasive due to upregulation of
proteins involved in epithelial-mesenchymal transition
(EMT) and cell invasion [17]. In smooth muscle cells, p53
limits podosome formation and cell invasion via expression
of microRNAs (miRNAs) that silence key podosome in-
ducers [18], and upregulation of caldesmon, a negative
regulator of actin polymerization [19]. Although similar
pathways may control invadopodia in cancer cells, the role
of p53 in regulating invadopodia has not been reported.
In this study, we show that Toca-1 upregulation in
TNBCs is due, at least in part, to loss of repression by
wild-type (WT) p53. We further demonstrate that p53
suppresses invadopodia, cell invasion and tumor metas-
tasis in breast cancers with WT p53. Silencing of Toca-1
can partially rescue the effects of p53 silencing in these
systems, consistent with its role in promoting breast cancer
cell invasion and tumor metastasis. Profiling of Toca-1
levels in human breast tumors revealed high Toca-1 levels
in HER2 and TNBC that frequently harbor p53 mutations,
and high Toca-1 transcript levels were associated with in-
creased risk of relapse in patients with TNBC.
Methods
Cell lines and cell culture
All of the cell lines used in this study were acquired
from American Type Culture Collection (ATCC, Rockville,
MD, USA), and were grown in their recommended media.
Briefly, Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 10% fetal bovine serum (FBS) was
used for BT-20, MCF-7, SKBR3, MDA-MB 435, MDA-
MB 468 and BT474 cells. RPMI 1640 supplemented
with 10% FBS was used for HBL-100, ZR75-1, T47D and
HCC-1500 cells. RPMI 1640 supplemented with 10% FBS,
1% 1 M HEPES, 1% sodium pyruvate, 1% D-glucose, 1%
glutamine and 1% penicillin/streptomycin was used forDU4475, HCC-1187 and HCC-38 cells. MCF10A cells
were grown in DMEM Nutrient Mixture F-12 HAM.
HCC-2157 were grown in DMEM-F12 media plus supple-
ments (10% FBS, 0.01 mg/mL transferrin, 0.02 mg/mL in-
sulin, 25 nM sodium selenite, 50 nM hydrocortisone,
1 ng/mL EGF, 0.01 mM ethanolamine, 0.01 mM phosphor-
ylethanolamine, 0.5% (w/v) bovine serum albumin (BSA),
0.5 mM sodium pyruvate, and 50 pM triiodothyronine).
Transfections
All plasmid transfections were done using Xtreme Gene
HP DNA (Roche, Basel, Switzerland) in serum-free
media followed by replacement with complete media.
Small interfering RNA (siRNA) against human p53
was from Santa Cruz Biotechnology (Dallas, TX, USA)
(sc-29435). Hiperfect transfection reagent (Qiagen, Venlo,
The Netherlands) was used to transfect siRNA.
Induction of p53
MCF-10A and DU4475 cells were plated 24 hours before
treatment with either Nutlin-3 (Sigma-Aldrich, St Louis,
MO, USA) or camptothecin (CPT, Sigma-Aldrich, Oakville,
ON, Canada) for 0 to 48 hours at doses indicated in figure
legends. Cells were then harvested, pelleted, lysed in
Nonidet-P40 (NP-40) lysis buffer (1% NP-40, 137 mM
NaCl, 20 mM Tris HCl pH 8, 10% glycerol and 2 mM
EDTA) and protein extract was collected. Immunoblot
analysis was then performed using Toca-1, p21, p53 and
β-actin antibodies.
RNA isolation and quantitative reverse
transcription-polymerase chain reaction (qRT-PCR)
Total RNA extraction was done using the RNeasy Plus Mini
Kit (Qiagen) according to the manufacturer’s instructions.
cDNA synthesis was performed with random hexamer
primers and Superscript II reverse transcriptase (Invitrogen,
Waltham, MA, USA). qRT-PCR was performed on cDNA
using human Toca-1 primers (for 5′ CAAACCAGGAAGT
CCGTGGGCC 3′; Rev 5′ ATGTCACACATGGCACAAAG
GTGC 3′) and GAPDH primers (for 5′ GCCTTCCGTGTC
CCCACTGC 3′; Rev 5′ CAATGCCAGCCCCAGCGTCA
3′) and SYBR Green JumpStart Taq ReadyMix kit (Sigma-
Aldrich; 58°C annealing, 40 cycles, BioRad iCycler (BioRad
Laboratories, Hercules, CA, USA). Transcript levels were
analyzed using the 2-ΔΔCT method [20]. Toca-1 mRNA levels
were normalized to glyceraldehyde-3-phosphate dehydrogen-
ase (GAPDH) mRNA levels.
Immunoblot analysis and antibodies
Non-commercial antibody mouse anti-Toca-1 was kindly
provided by Giorgio Scita (IFOM, Italy) as previously
described [13]. Commercial sources of antibodies in-
cluded anti-p53 (DO-1; human-specific; sc-126), anti-p21
(sc-56335), anti-β-Actin (sc-47778), and immunoglobulin
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Cruz Biotechnology. For MTLn3 cell studies, mouse
anti-rat p53 antibody was used (1C12; Cell Signaling
Technology, Beverly, MA. USA). Secondary antibodies
included horseradish peroxidase (HRP)-conjugated anti-
mouse or anti-rabbit IgGs (GE Healthcare, Little Chalfont,
UK). Immunoblot analyses were performed as described
previously [11].
Chromatin immunoprecipitation (ChIP) assays
HBL-100 and DU4475 cells were treated with or without
CPT (10 μM) for 24 hours prior to harvesting. For assays
with ectopic WT p53 expression, HCC1806 cells were
transfected with WT p53 for 24 to 48 h prior to harvesting.
ChIP assays were performed as described previously [21].
Briefly, cells were crosslinked with 1% formaldehyde
(Sigma-Aldrich) followed by lysis of cells in RIPA buffer
(50 mM Tris pH 8.0, 5 mM EDTA, 150 mM NaCl, 1% NP-
40, 0.5% DOC, 0.1% SDS) and sonication (10 sec on/off
cycle, 20 pulses performed four times; Thermo Fisher
Scientific (Waltham, MA, USA, Sonic Dismembrator
Model 500). DNA-protein complexes were immunoprecipi-
tated using antibody (DO-1) against p53, acetylated histone
H3 (H3K14ac) antibody (#06-599, EMD Millipore, Billerica,
MA, USA), or a control IgG (Santa Cruz Biotechnology).
After reversal of crosslinks and purification (Qia-quick PCR
Purification Kit, Qiagen), DNA was subjected to PCR using
the primers from the predicted binding sites of p53 within
intron 2 of toca1 (SA Biosciences, Frederick, MD, USA
(GPH1006475 (-) (01A)), or p21 promoter primers. The
acetyl-histone H3 (H3K14Ac) precipitates were subjected
to qPCR using primers from proximal promoter region of
Toca-1. PCR reactions were performed using 5 μL of the
DNA from the immunoprecipitations or the 2 μL of DNA
from the input as template. PCR cycling conditions were as
follows: 94°C for 3 min; then 35 cycles of 94°C for 45 s,
58°C for 45 s, and 72°C for 45 s; followed by 10 min at
72°C as final extension.
Stable silencing of p53 and Toca-1
For silencing of rat p53 in MTLn3 cells, an LMP retroviral
vector expressing a p53 short hairpin RNA (shRNA) was
previously described [19]. The system for lentiviral deliv-
ery of Toca-1 shRNA was also described previously [11].
Briefly, MTLn3 cells were incubated with retroviral or len-
tiviral particles individually or combined prior to selection
with puromycin (2 μg/ml) and cell pools were passaged
several times prior to testing for p53 and Toca-1 silencing.
To test for effects of p53 and Toca-1 silencing on cell via-
bility, cells (5,000) were seeded in 96-well plates in tripli-
cate for 18 hours, and analyzed following addition of
AlamarBlue™ for 5 hours using a plate-reading spectro-
photometer to measure absorbance at 570 nm. Cell
growth assays were conducted by plating 50,000 cellsfrom each group in 60 mm plates on day 0, followed
by total viable (trypan blue-negative) cell counts on days 2
and 3 using a hemocytometer.
Extracellular matrix degradation assays
MTLn3 control, sh-p53 and sh-p53/sh-Toca-1 cells were
seeded on gelatin-coated glass coverslips (15,000 cells)
containing a layer of thin gelatin, prepared as described
previously [4]. After incubation for 16 h, cells were fixed,
permeabilized and stained with Alexa Fluor-488 Phal-
loidin (Life Technologies Inc., Burlington, ON, Canada).
Epifluorescence microscopy was performed and the
areas of ECM digestion beneath the cells that were
stained with Phalloidin were quantified as digestion area
per cell using Image Pro Plus software (Media Cyber-
netics, Bethesda, MD, USA). At least 100 cells were
quantified for each condition and cell line.
Transwell invasion assays
Invasion assays were performed as described previously
[11]. Briefly, transwell inserts (8 μm pore) were coated
with 100 μl of ice-cold Matrigel (1:5 dilution in DMEM
with 0.5% FBS) for invasion, or coated with 0.1% (w/v)
gelatin for migration assays, and incubated at 37°C for
30 min. A total of 50,000 cells were added in the upper
chamber, which was placed in a 24-well plate containing
serum as a chemoattractant. After overnight incubation,
the filters were fixed in 4% paraformaldehyde, cells and
Matrigel on the top of the filter were removed and the
cells attached to the underside of the filter were stained
with DAPI. Epifluorescence microscopy was performed
to detect nuclei of cells that migrated to the underside
of the filters. Scoring of invading cells from four separate
fields was performed for triplicate filters using the Image
Pro Plus software (Media Cybernetics).
Mammary orthotopic tumor xenograft assays
All tumor xenograft assays were performed using
Rag2−/−:IL-2Rγc−/− mice (BALB/c background) as previ-
ously described [11,22]. Animals were housed in a specific
pathogen-free facility (Queen’s University Animal Care
Services), with ventilated cages and sterilized food and
water supply. All procedures with mice were approved by
the Queen’s University Animal Care Committee. MTLn3
control, sh-p53 and sh-p53/sh-Toca-1 cells were grown to
70 to 85% confluence before trypsinization and counting.
For xenograft assays, 0.5 × 106 cells were injected into the
right thoracic mammary fat pads in a volume of 50 μl of
50% Matrigel using a hypodermic syringe. At end points
of 4 weeks mice were sacrificed and primary tumor mass
recorded. Several tissues were removed for detection of
metastases, which were primarily observed in the lungs.
The primary tumors and lungs from each mouse were used
for histological analysis. Samples were fixed in formalin
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with hematoxylin and eosin (H&E). H&E-stained sections
were scanned using the Aperio CS digital slide scanner
(Queen’s Laboratory for Molecular Pathology) and ana-
lyzed with ImageScope software (Aperio Technologies,
Vista, CA, USA). The number of metastases and overall
lung area were measured in a blinded fashion.
Immunohistochemistry (IHC)
Human breast cancer tissue microarrays (T086b, BR10010a,
BR963 and BR953, US Biomax, Inc., Rockville, MD, USA)
were stained using the Discovery XT Staining System
(Ventana Medical Systems, Inc. Tucson, AZ, USA).
Antigens were retrieved with an EDTA pH 8.0 solution
and incubated with rabbit anti-p53 (DO-1) and Toca-1
antibody as used previously [11,23]. Staining was visualized
with DAB treatment and a hematoxylin counterstain. Mi-
croarrays were scanned using the Aperio CS digital slide
scanner (Queen’s Laboratory for Molecular Pathology) and
analyzed with ImageScope software (Aperio). Tumor-
specific H-scores were calculated based on positive
pixel intensity according to the formula: (% weak positive
X 1) + (% positive X 2) + (% strong positive X 3). The p53
IHC scoring was grouped according to the extreme posi-
tive (EP), extreme negative (EN), and non-extreme (NE)
categories that were recently shown to best relate to p53
mutation status and outcomes [24]. Toca-1 H-scores were
reported according to p53 EP/EN or NE groups, and ana-
lyzed by Student’s t test.
Results
Toca-1 levels correlate with p53 status in breast cancer
cell lines
We previously showed that Toca-1 levels were high in
TNBC cell lines and a subset of invasive ductal carcin-
omas [11]. Since TNBCs have a high frequency of p53
mutations [15], we tested Toca-1 levels relative to p53
status in a panel of cell lines. This included two immor-
talized breast epithelial, normal-like cell lines (HBL-100
and MCF-10A), and a panel of human breast cancers
with either WT p53 (BT-20, ZR75-1, MCF-7, DU4475),
or mutant p53 (BT-474, T47D, SK-BR3, MDA-MB-
435, HCC2157, MDA-MB-468, HCC-1500, HCC-1187,
HCC-38). Lysates were subjected to immunoblot (IB)
with Toca-1 and p53 antibodies. This analysis revealed
high levels of Toca-1 in the vast majority of mutant p53
cell lines compared to WT p53 (Figure 1A). Similar re-
sults were observed for p53, with high levels of mutant
p53 accumulating in these cells compared to WT p53
(Figure 1A; actin served as a loading control). In the case
of HBL-100 cells, the high levels of WT p53 are likely
due to presence of SV40 viral antigens [25] that cause
p53 stabilization [26]. Using densitometry, the average
levels of Toca-1 relative to β-actin was significantlyhigher in mutant p53 cell lines compared to WT p53
cell lines (Figure 1B). To test whether a similar correl-
ation between p53 status and Toca-1 expression exists
at the level of gene expression, we profiled Toca-1
mRNA levels across the same panel of cell lines by qRT-
PCR. Toca-1 transcript levels were normalized to human
GAPDH, and were found to be considerably higher
in mutant p53 compared to WT p53 cancer cell lines
(Figure S1 in Additional file 1). It is worth noting that
the lowest levels of Toca-1 transcripts were observed in
normal-like breast epithelial cell lines (Figure S1 in
Additional file 1). Together, these results suggest that
p53 status may dictate the levels of Toca-1 in normal cells
and cancer cell lines.
Since mutant p53 confers both loss of WT p53 func-
tion, and gain-of-function effects on a large number of
target genes [23,27,28], we asked whether Toca-1 ex-
pression was induced or dependent on mutant p53 ex-
pression. To test this, endogenous Toca-1 levels were
analyzed upon ectopic expression of two frequently ob-
served p53 mutants (p53-Ala143 and p53-Trp248) in
p53-null HCC1806 cells. Surprisingly, the overexpression
of either p53 mutant had no effect on Toca-1 levels
(Figure 1C). To reinforce these results, siRNA-mediated
knockdown (KD) of mutant p53 expression in HCC38
(TNBC) and SKBR3 (HER2) was performed. Although
the levels of mutant p53 were greatly reduced in both cell
lines, the levels of Toca-1 were unchanged (Figure 1D).
These results suggest that overexpression of mutant p53
and gain-of-function effects are unlikely to explain the up-
regulation of Toca-1 in these breast cancer cell lines.
WT p53 suppresses Toca-1 expression
We next tested whether Toca-1 expression could be
repressed by physiological induction of endogenous
p53 using camptothecin (CPT), a DNA-damaging agent
that causes rapid stabilization of p53 [29]. Normal-like
MCF10A cells were treated with increasing doses of
CPT for 24 h (2 to 20 μM; DMSO served as vehicle con-
trol) prior to IB analysis of Toca-1, p53 and p21WAF1,
which served as a positive control for p53 activation. As
expected, CPT treatment led to increased p53 and p21
protein levels, and this coincided with reduced levels of
Toca-1 at both the protein and mRNA levels (Figure S2
in Additional file 2). In DU4475 cells expressing low
levels of WT p53, CPT treatment (1 to 8 μM) also led to
a significant reduction in Toca-1 protein and mRNA
levels along with the expected stabilization of p53 and
upregulation of p21 (Figure 2A,B). We next analyzed the
kinetics of p53 effects on Toca-1 expression by treating
DU4475 cells with CPT (4 μM) for 0 to 24 h. We ob-
served maximal levels of p53 and p21 proteins within
12 hours of CPT treatment, and a corresponding de-
crease in Toca-1 protein and mRNA levels at 18 and
Figure 1 Toca-1 expression correlates with p53 status in breast cancer cell lines. (A) Lysates from the indicated normal-like breast epithelial
and breast cancer cell lines were grouped according to either WT or mutant p53 and subjected to IB with Toca-1, p53 and β-Actin antibodies.
(B) Densitometric analysis of Toca-1 protein levels relative to β-actin in WT p53 and mutant p53 cell lines (mean ± SD); *depicts a significant difference
based on paired Student’s t test (P <0.05)). (C) p53-null HCC1806 cells were transfected with mutant p53 (Ala-143, Trp-248) plasmids and the levels of
Toca-1 and p53 were assessed by IB (actin served as a loading control). (D) siRNA mediated silencing of endogenous mutant p53 in HCC-38 and SKBR3
cell lines. Levels of Toca-1 and p53 were assessed by IB (actin served as a loading control). IB, immunoblot; siRNA, small interfering RNA; SD, standard
deviation; Toca-1, transducer of Cdc42-mediated actin assembly; WT, wild-type.
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we used Nutlin-3, a small molecule inhibitor of MDM2
that prevents targeting of p53 for proteasomal degrad-
ation. As with CPT, we observed a dose-dependent effect
of Nutlin-3 on the stabilization of p53 and downregula-
tion of Toca-1 in DU4475 cells (Figure 2E). These re-
sults are consistent with WT p53 stabilization, and not
DNA damage per se, triggering downregulation of Toca-1
in breast cancers expressing WT p53.
To test whether WT p53 expression is sufficient for
Toca-1 downregulation, p53-null HCC1806 cells were
transfected with increasing amounts of a WT p53 ex-
pression plasmid. At the highest amount of plasmid cor-
responding to maximal p53 and p21 levels, we observed
decreased levels of Toca-1 (Figure 2F). As an additional
control, co-transfections of WT p53 plasmid with a p53
siRNA impaired the downregulation of Toca-1 in this
model (Figure 2G). Thus, our data suggests that the
loss-of-function effects of WT p53 are responsible for
the elevated levels of Toca-1 in the breast cancer cell
lines with p53 mutations.Toca-1 is a novel p53 target gene subjected to epigenetic
regulation by p53
Since we observed similar suppression of Toca-1 protein
and mRNA with WT p53 stabilization in these breast
cancer models, we investigated whether Toca-1 is a pre-
viously unidentified p53 target gene. The Toca-1 gene
(toca1/fnbp1l) includes 16 exons spanning 120 kb on
chromosome 1 (1p22.1), and although no p53 response
elements were predicted in the promoter region, a
potential binding site was present in intron 2 of toca1
(Figure 3A). This site included a perfect consensus
for the first repeat, and an imperfect second repeat
(Figure 3A). To test whether WT p53 binds this site,
CPT-treated normal-like breast epithelial cells (HBL-100)
and DU4475 breast cancer cells were subjected to ChIP
assays using p53 antibody (DO-1) or a control IgG. PCR
analyses revealed recovery of toca1 intron 2 with p53 in
CPT-treated cells compared to untreated or control IgG
(Figure 3B). As expected, this also led to increased recov-
ery of the p21 promoter region bound to p53 in both cell
lines (Figure 3B). To quantify and extend on these results,
Figure 2 WT p53 downregulates Toca-1. (A) DU4475 cells were treated with indicated doses of CPT) for 24 h, and lysates subjected to IB with
Toca-1, p53 and p21 antibodies. (B) Toca-1 mRNA levels were analyzed in DU4475 cells treated as above by qRT-PCR (2-ΔΔCT values for Toca-1
were normalized to GAPDH for each concentration of the drug, and graph depicts transcript levels relative to DMSO-treated cells (mean ± SD;
triplicate samples)). (C) DU4475 cells were treated with CPT (4 μM) for the indicated times, and analyzed by IB as above. (D) DU4475 cells were
treated with CPT (4 μM) for the indicated times were subjected to qRT-PCR analysis of Toca-1 mRNA levels as above. (E) DU4475 cells were
treated with Nutlin-3 at indicated doses for 24 hours, and subjected to IB analysis as above. (F) p53-null HCC1806 cells were transfected with WT
p53 expression plasmid (0 to 8 μg) for 24 to 48 hours, and levels of Toca-1, p53 and p21 were assessed by IB (β-actin served as a loading control).
(G) HCC1806 cells were transfected with WT p53 plasmid, and after 24 hours with a siRNA against p53 prior to harvesting at 48 hours. Lysates
were subjected to IB with Toca-1, p53 and β-actin antibodies. CPT, camptothecin; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; IB,
immunoblot; qRT-PCR, quantitative reverse transcription-polymerase chain reaction; SD, standard deviation; siRNA, small interfering RNA;
Toca-1, transducer of Cdc42-mediated actin assembly; WT, wild-type.
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served 40-fold and 20-fold enrichment in p53 binding to
p21 promoter and toca1 intron 2 with CPT treatment,
respectively (Figure 3C). We also tested primers in the
proximal promoter region of toca1, but observed no en-
richment of background levels (Figure 3C). Similar results
were observed for ectopic expression of WT p53 in
HCC1806 cells, with 70-fold and 15-fold enrichment in
p53 binding to p21 promoter and toca1 intron 2, respect-
ively, compared to IgG control (Figure 3D,E). In this sys-
tem, no increased association of p53 with the proximal
promoter of toca1 was observed (data not shown). In
addition, neither of the toca1 promoter or intron 2 regions
were recovered with mutant p53 in ChIP assays performedwith MDA-MB-231 cells (data not shown). Together,
these results identify a functional binding site for p53
within intron 2 of toca1.
Previous studies have identified epigenetic effects of
WT p53 activation on its target genes, including effects
on histone H3 acetylation at Lys14 (H3K14Ac) and
methylation at Lys27 that are associated with transcrip-
tionally active and silent states, respectively [30]. To test
this, we extended our ChIP assays on HCC1806 cells
transfected with WT p53 plasmid using H3K14Ac anti-
body, and observed decreased recovery of the toca1
promoter region with this chromatin mark upon p53
transfection (Figure 3F). Similar results were obtained in
DU4475 cells treated with CPT to induce stabilization of
Figure 3 (See legend on next page.)
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Figure 3 p53 binding and altered chromatin marks at the toca1 gene. (A) toca1 gene organization and a predicted p53 binding site within
intron 2 is shown. Below, the consensus sequence for p53 binding is shown (R = A/G, W = A/T, and Y = C/T) relative to the predicted site, with
lowercase letters denoting deviations from the consensus. (B) HBL-100 and DU4475 cells were treated with or without CPT (8 μM) to stabilize
endogenous WT p53, and ChIP assays performed using control IgG or p53 antibody. Input material and ChIP assays were analyzed by PCR for
intron 2 of toca1 and p21 promoter region as a positive control. Inverted images of representative ethidium bromide gels are shown. (C) DU4475
cells treated as above were subjected to ChIP assays and analyzed by qPCR. Graph depicts the fold change in p53 binding to the p21 promoter
(positive control), or toca1 intron 2, or toca1 proximal promoter (mean ± SD; triplicate samples). (D and E) HCC1806 cells were transfected with or
without WT p53 plasmid and ChIP assays performed with control IgG or p53 (DO-1) antibodies. qPCR analyses for the p53 binding site within p21
promoter region (D) and intron 2 of toca1 (E) are shown (2-ΔΔCT values for p53 antibody were normalized to IgG; graph depicts the fold change
in recovery with p53; mean ± SD; triplicate samples). (F and G) ChIP assays for acetylated histone H3 (H3K14Ac) were analyzed by qPCR for the
proximal promoter region of Toca-1 in HCC1806 cells transfected with WT p53 (F) and CPT-treated DU4475 cells (G; 2-ΔΔCT values for p53 antibody
were normalized to IgG; graph depicts the fold change in recovery with acetylated histone H3; mean ± SD; triplicate samples). ChIP, chromatin
immunoprecipitation; CPT, camptothecin; IgG, immunoglobulin G; qPCR, quantitative polymerase chain reaction; SD, standard deviation; Toca-1,
transducer of Cdc42-mediated actin assembly; WT, wild-type.
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of the toca1 promoter region with the H3K14Ac mark
(Figure 3G). These results are consistent with active tran-
scription of toca1 under conditions of p53 degradation via
MDM2 (murine double minute-2), and the loss of this
open chromatin mark upon p53 activation and binding
within intron 2 of the toca1 gene. This may be due to
increased recruitment of histone deacetylase complexes
(HDACs) that are known to associate with activated p53
and cause repression of some target genes [31-34].
p53 suppresses invadopodia formation and invasion of
MTLn3 cells in a Toca-1-dependent manner
To further relate the p53/Toca-1 axis in the context of
breast cancer progression and metastasis, we used rat
mammary adenocarcinoma MTLn3 cells that express
WT p53 and have been used extensively to model breast
cancer metastasis [3,35,36]. Further, we recently used
this cell model in our study that identified Toca-1 in
promoting breast cancer cell invasion and tumor metas-
tasis [11]. First, we confirmed that WT p53 also downre-
gulates rat Toca-1 levels in MTLn3 cells upon treatment
with CPT. We observed maximal p53 stabilization at
24 hours, and reduced levels of Toca-1 (Figure 4A). To-
gether with our results in human breast cell lines, this
provides further support for a WT p53 pathway that
suppresses Toca-1 expression. To test whether p53 regu-
lates the invasive potential of MTLn3 cells, we used
retroviral or lentiviral delivery of shRNAs against p53
and Toca-1, respectively, to achieve stable silencing of
p53 and Toca-1. We observed efficient depletion of p53
in sh-p53 cells, and this correlated with increased levels
of Toca-1 compared to sh-control or parental MTLn3
cells (Figure 4B). These results are consistent with our
findings linking WT p53 to Toca-1 levels in human breast
cancer cells. In sh-p53/sh-Toca-1 cells, we observed a
complete depletion of both Toca-1 and p53 (Figure 4B).
Since p53 was recently shown to repress podosome
formation and invasiveness of smooth muscle cells andfibroblasts [18,19], we tested the effects of p53 silencing
on invadopodia formation in MTLn3 cells. MTLn3 con-
trol and sh-p53 cells were plated on coverslips coated
with fluorescent ECM (thin gelatin) for 16 hours prior
to staining of F-actin. Epifluorescence micrographs were
obtained to visualize ECM degradation spots relative to
F-actin dots that mark invadopodia. As expected, control
MTLn3 cells degraded ECM, but the amount of degrad-
ation spots and F-actin dots was enhanced with p53 silen-
cing (Figure 4C). Quantification of these results revealed a
2.5-fold increase in ECM digestion area per cell with p53
silencing compared to control MTLn3 cells (Figure 4D). A
parallel analysis of p53/Toca-1 double KD cells revealed a
partial rescue of the effects of p53 silencing (Figure 4C,D).
These results are consistent with Toca-1 acting as a posi-
tive regulator of invadopodia [11], and provide evidence
that p53 mutation status likely contributes to the ability of
cancer cells to form invadopodia through altered expres-
sion of invadopodia regulatory proteins.
To test whether p53 also regulates the ability of
MTLn3 cells to invade through ECM, MTLn3 control,
sh-p53 and sh-p53/sh-Toca-1 cells were plated in trans-
well chambers overlayed with Matrigel, and invasion to-
ward the lower chamber was measured after 24 hours.
We found that silencing of p53 significantly increased the
number of invading cells compared to control MTLn3
cells (Figure 4E). However, dual silencing of Toca-1 and
p53 led to a significant reduction in cell invasion com-
pared to sh-p53 cells, which returned to near baseline
levels in control MTLn3 cells (Figure 4E). Taken together,
these results provide novel evidence for p53 suppression
of invadopodia in cancer cells, and identify Toca-1 as a
key participant in ECM degradation and cell invasion
upon loss of p53.
Silencing p53 enhances MTLn3 tumor growth and
metastasis and is partially dependent on Toca-1
To investigate contributions of the p53/Toca-1 axis to
breast cancer progression and mestastasis, we performed
Figure 4 (See legend on next page.)
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Figure 4 p53 suppresses Toca-1 expression and invadopodia formation in MTLn3 cells. (A) MTLn3 cells were treated with CPT (4 μM) for
indicated times and analyzed by IB with Toca-1, p53 and ERK antibodies (ERK served as a loading control). (B) MTLn3 cells with stable silencing of
p53 and Toca-1 alone, or in combination, was tested by IB with Toca-1, and p53 antibodies (α-actinin served as a loading control). (C) Representative
epiflourescence micrographs for MTLn3 control, sh-p53 and sh-p53/sh-Toca-1 cells plated on TRITC-gelatin (ECM) and stained with phalloidin (F-actin;
merge indicates an overlay of both channels). (D) Graph depicts the ECM degradation area relative to total cell area for cell lines described above
(mean ± s.e.m.; triplicate samples with 12 fields and >40 cells analyzed; *depicts a significant difference based on paired Student’s t test (P <0.05)).
(E) Transwell invasion assays for MTLn3 control, sh-p53 and sh-p53/sh-Toca-1 cells. The graph depicts the number of cells per field that had invaded
through the ECM to the underside of the filter for each cell line (mean ± s.e.m.; 12 fields were analyzed from triplicate filters for each cell line; * and **
depict significant differences between the indicated groups (P <0.05 and P <0.01, respectively) based on paired Student’s t test; dashed line indicates
no significant difference (n.s.) based on paired Student’s t test; results are representative of two independent experiments). CPT, camptothecin; IB,
immunoblot; ECM, extracellular matrix; ERK, extracellular signal-regulated kinases; F-actin, filamentous actin; s.e.m., standard error of the mean; Toca-1,
transducer of Cdc42-mediated actin assembly; WT, wild-type.
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control, sh-p53 and sh-p53/sh-Toca-1 cells in Rag2−/−:
IL2Rγc−/− mice. After 5 weeks, mammary tumors were
harvested, and we observed a significant increase in
tumor mass with silencing of p53 compared to control
(Figure 5A). However, a significant reduction in tumor
mass was observed upon combined silencing of Toca-1
and p53. These differences in tumor growth were not
due to inherent differences in cell viability or growth
rates in vitro (Figure S3 in Additional file 3). Tumor ho-
mogenates were subjected to IB with p53 and Toca-1
antisera, which demonstrated the continued silencing of
these proteins during the tumor study (Figure 5B). Since
this model results in metastasis to the lungs of these
mice [11,22], we analyzed lung tissue sections for pres-
ence of metastatic nodules. Interestingly, we observed
increased lung metastases with p53 silencing in MTLn3
tumor-bearing mice (Figure 5C,D). However, combined
silencing of Toca-1 and p53 led to a partial rescue of the
lung metastasis phenotype compared to control MTLn3
(Figure 5C,D). To address whether these defects might
relate to altered tumor mass between groups, we tested
for a correlation in our MTLn3 xenograft model. We
observed a positive correlation between tumor mass and
the numbers of lung metastases that was significant, but
with a poor correlation co-efficient (R2 = 0.377; Figure
S4 in Additional file 4). However, this is unlikely to ex-
plain the effects of combined p53 and Toca-1 silencing
since differences in tumor mass were quite modest com-
pared to sh-p53 tumors (Figure 5A). Together, these re-
sults provide evidence for suppression of breast tumor
progression and metastasis by WT p53, and that Toca-1
contributes to the increased metastasis with p53 loss-of-
function.
Toca-1 is highly expressed in human breast cancer
subtypes with frequent p53 mutations and a potential
marker of poor prognosis
Having established a novel link between Toca-1 and p53,
we aimed at expanding our analysis to human primary
breast cancers. Human breast tumor tissue microarrayswith known ER, PR, and HER2 status were stained with
Toca-1 and p53 antibodies by IHC. As expected, the levels
of p53 and Toca-1 varied greatly within tumor cores
(Figure 6A). In the case of p53, we grouped these cases as
uniformly negative (extreme negative, EN), intermediate
or variable levels (non-extreme, NE), and uniformly posi-
tive (extreme positive, EP) based on a recent study show-
ing that the majority of extreme p53 cases (EP/EN)
correspond to p53 mutations [24]. Interestingly, this study
also showed that p53 EP/EN patients had worse overall
survival. To relate Toca-1 levels to p53 IHC staining cat-
egories, we determined H-scores for Toca-1 in 63 cases
with p53 status of EP/EN, and 63 cases with NE status
(Figure 6B). Interestingly, there was significantly higher
median expression of Toca-1 in p53 EP/EN category com-
pared to NE (Figure 6B). We also extended the analysis of
Toca-1 levels to the major molecular subtypes, including
luminal, HER2 and TNBC. Consistent with the increased
frequency of p53 mutations in HER2 and TNBC subtypes
[37], and our profiling of Toca-1 in breast cancer cell lines
[11], we observed significantly increased Toca-1 expres-
sion levels in these subtypes compared to luminal tumors
(Figure 6C,D). This is also consistent with increased fre-
quency of extreme p53 expression by IHC (EP/EN) in
HER2 and TNBC compared to luminal [24], and their
relative risk of metastasis [38,39]. Thus, higher Toca-1
levels may be due to loss of WT p53 pathways in HER2 or
TNBC tumors. To test whether high Toca-1 levels corre-
lated with clinical outcomes, we used the Kaplan-Meier
Plotter analysis tool [40] to analyze Toca-1 transcript
levels in breast cancer microarray datasets. Interestingly,
we observed a significant association between high Toca-1
transcript levels and increased risk of relapse in basal
breast cancer patients (Figure 6E; hazard ratio = 1.43,
P <0.05). Since the majority of TNBCs have been classi-
fied as basal breast cancers [41,42], the reduced relapse-
free survival in patients with high Toca-1 levels reported
here is consistent with our functional studies implicating
Toca-1 in promoting breast cancer cell invasion and
tumor metastasis downstream of EGFR and Cdc42. Thus,
we postulate that in normal cells, or cancer cells with
Figure 5 p53 silencing enhances MTLn3 tumor progression and lung metastasis and partial rescue with Toca-1 silencing. Mammary
orthotopic xenograft assays using MTLn3 control, sh-p53 and sh-p53/sh-Toca-1 cells were analyzed at 5 weeks post injection of Rag2-/-IL2Rγc-/-
mice. (A) Graph depicts primary tumor mass for each mouse injected with the indicated cell line (mean ± SD; n = 5 mice/group; significant
differences between groups based on paired Student’s t test are indicated by *P <0.05 or ***P <0.001). (B) Levels of Toca-1 and p53 in the
tumor homogenates were analyzed by IB (β-actin served as a loading control; dashed lines indicating removal of additional lanes). (C) Representative
H&E-stained sections of lungs from mice harboring mammary tumors for the indicated cell lines are shown (arrows depict metastatic nodules).
(D) Graph depicts the number of metastases per lung for each mouse injected with the indicated cell line (mean ± SD; n = 5 mice/group;
significant differences between groups based on paired Student’s t test are indicated by *P <0.05 or ***P <0.001). H&E, hematoxylin and eosin;
IB, immunoblot; SD, standard deviation; Toca-1, transducer of Cdc42-mediated actin assembly.
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be suppressed at multiple points by WT p53 (Figure 6F).
Discussion
The current study describes a novel mechanism to limit
expression of the breast cancer invasion and metastasis-
promoting protein Toca-1, by the tumor suppressor p53.
Breast cancers with loss of p53, or frequent p53 muta-
tions (HER2, TNBC), have high rates of metastasis
[38,39]. This is due to activation of EGFR/HER2 and Src
signaling pathways in these cancers, leading to for-
mation of invadopodia, and increased rates of metastasis
[43-46]. We previously reported that Toca-1 promotesbreast cancer cell invasion and tumor metastasis [11], and
were interested in defining how Toca-1 expression is regu-
lated. Here, we report that Toca-1 expression in normal
breast epithelial cells and breast cancers is significantly
associated with p53 status. Activation of WT p53 led to
decreased expression of Toca-1, which involves the bind-
ing of p53 within intron 2 and decreased open chromatin
marks within the promoter region of the toca1 gene. Using
MTLn3 breast cancer cells expressing WT p53, we pro-
vide evidence that p53 can partially suppress invado-
podia, cell invasion, and tumor metastasis. The combined
silencing of p53 and Toca-1 significantly reduced the phe-
notypes observed with p53 silencing alone. Lastly, we
Figure 6 (See legend on next page.)
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Figure 6 Toca-1 is highly expressed breast cancer subtypes with frequent p53 mutations and is associated with poor prognosis.
(A) Representative micrographs showing the range of expression of Toca-1 and p53 in human invasive ductal carcinomas based on IHC staining.
(B) Graph depicts quantification of Toca-1 levels using H-score analysis according to p53 IHC staining patterns (EP/EN, extreme positive/extreme
negative; NE, non-extreme or intermediate levels) in 63 human ductal carcinomas (*indicates a significant difference between groups based on
paired Student’s t test, P <0.05). (C) Representative micrographs showing results of Toca-1 IHC staining in human breast cancer subtypes,
including luminal, HER2 and TNBCs. (D) Graph depicts quantification of Toca-1 IHC staining using H-score analysis, and grouped by molecular
subtypes (luminal, HER2 and TNBC; significant differences between groups based on paired Student’s t test are indicated by *P <0.05 or **P <0.01).
(E) Kaplan-Meier Plotter analysis of basal breast cancer patients with high or low Toca-1 transcript levels according to relapse-free survival (n = 581;
HR = 1.5, logrank P <0.01). (F) A schematic model depicting known targets of WT p53 (EGFR, Cdc42, Toca-1) that upon p53 loss or mutation,
promote formation of invadopodia, invasion through ECM, and tumor metastasis. ECM, extracellular matrix; EGFR, epidermal growth factor
receptor; IHC, immunohistochemistry; HER2, human epidermal growth factor receptor 2; HR, hazard ratio; TNBCs, triple-negative breast cancers; Toca-1,
transducer of Cdc42-mediated actin assembly.
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subtypes that frequently harbor mutations in tumor
suppressor p53 [47], and also with extreme IHC stain-
ing (negative or positive) of p53 in our invasive ductal
carcinoma tissue microarrays. Based on these observa-
tions, we propose a model whereby WT p53 inhibits
the EGFR/Cdc42/Toca-1 signaling axis in normal cells,
and some breast cancers, to suppress the invasive pheno-
type of these cells (Figure 6F).
We postulate that p53 suppresses Toca-1 in some can-
cer cells to limit their invasive potential. The loss of WT
p53 via frequent mutations observed in HER2 and
TNBCs, likely explains the high levels of Toca-1 in these
tumors and cell lines. However, the mutant p53 is more
stable than WT p53, and accumulates in the nucleus
and interacts with many oncoproteins resulting in gain-
of-function effects [48]. In terms of Toca-1 expression,
we observed no effect of either overexpression of mutant
p53 or silencing the endogenous mutant p53 in HER2 or
TNBC cell lines. Together with evidence that Toca-1 is
repressed by WT p53, the higher levels of Toca-1 we ob-
served in HER2 and TNBC tumors and cell lines, is
likely explained by loss of WT p53-mediated gene re-
pression. Our results also identify a p53 binding site
within intron 2 of toca1, and reduced open chromatin
marks within the promoter region of toca1. This mech-
anism is consistent with the repression of Survivin by
p53, which involves recruitment of HDACs to the Survi-
vin promoter region leading to chromatin condensation
[32-34]. Thus, a similar mechanism may be involved in
the repression of Toca-1 following p53 activation. Other
known p53 target genes with intronic p53 response
elements include GADD45 [49,50], and pregnancy-
associated plasma protein A [23]. Future studies will
be required to fully define the epigenetic marks and p53-
associated factors involved in this mechanism to limit
Toca-1 expression.
Although the best characterized tumor suppressor role
for p53 involves the DNA damage response, there is a
growing appreciation for its role as a cell invasion sup-
pressor [17]. A number of p53 target genes have beenimplicated in cancer cell invasion and metastasis [51-54].
For example, a recent study showed that mammary-
specific inactivation of E-cadherin and p53 leads to pleo-
morphic invasive lobular carcinoma in mice [52]. In
stromal fibroblasts, p53 has been shown to attenuate
cancer cell migration and invasion by repressing SDF-1/
CXCL12 expression [53]. WT p53 also regulates MET re-
ceptor and has been shown to control cell motility and in-
vasion in ovarian cancer [54]. WT p53 also inhibits EGFR
expression, which is a key pathway in TNBC metastasis
[15]. Other targets of p53 are caldesmon, a negative regu-
lator of Src-induced podosome formation and ECM deg-
radation [19], and microRNAs (miR-143/miR-145) that
target key pathways leading to podosome formation [18].
Although the latter studies suggest that WT p53 will sup-
press invadopodia, due to similarities in pathways and
components for podosomes, this has not been previously
reported. Here, we used the MTLn3 model with stable si-
lencing of p53 to show that cell invasion and tumor me-
tastasis remain under some level of control by p53 in this
breast cancer model. Furthermore, the loss of WT p53-
mediated suppression of Toca-1 contributes the increased
cell invasion and tumor metastasis upon p53 silencing in
this breast cancer model. Importantly, increased expres-
sion of Toca-1 in human breast tumors from HER2 and
TNBC subtypes with frequent p53 mutations, further sup-
ports the relevance of this p53/Toca-1 signaling axis in
cancer progression. Certainly, the increased risk of relapse
in basal breast cancer patients with high Toca-1 transcript
levels would fit with our evidence for Toca-1 promoting
metastasis, but should be investigated further at the pro-
tein level.
Conclusions
In conclusion, our results demonstrate that accumula-
tion of WT p53 leads to repression of Toca-1, and loss
of this regulatory axis likely contributes to upregulation
of Toca-1 in highly metastatic cancers (Figure 6F). Based
on our study, we identify Toca-1 as a pro-invasion/pro-
metastasis protein that is downregulated by WT p53 in
both rat and human breast cancer models. This may
Chander et al. Breast Cancer Research  (2014) 16:3413 Page 14 of 15reflect the fact that Toca-1 is capable of scaffolding and
activating numerous regulators of actin assembly at cell
protrusions that facilitate motility and invasion. Thus,
limiting Toca-1 levels could reduce a number of path-
ways that attempt to activate these actin-regulatory pro-
teins in normal cell and cancer cells.
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